Why Mesoblast's Move Into DMD Warrants A Speculative Buy (Upgrade)

Mesoblast (MESO) is upgraded to a speculative Buy as Ryoncil outperforms in pediatric SR-aGVHD and advances rapidly into a registrational DMD trial. Ryoncil's DMD opportunity is underappreciated, with a modeled $2B peak sales and $1.18B risk-adjusted NPV, enabled by FDA confidence in its safety profile. SR-aGVHD remains a niche but high-margin market, with Ryoncil nearing $100M in sales and strong launch adoption, though adult expansion faces competition.